# Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

> **NCT06912529** · PHASE2 · TERMINATED · sponsor: **Universität Münster** · enrollment: 1 (actual)

## Conditions studied

- B-cell Lymphoma Refractory
- B-cell Lymphoma Recurrent

## Interventions

- **PROCEDURE:** Leukapheresis
- **DRUG:** Bridging Therapy
- **DRUG:** Lymphodepletion
- **GENETIC:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT06912529
- **Lead sponsor:** Universität Münster
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-03-13
- **Primary completion:** 2025-07-25
- **Final completion:** 2025-07-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Funder of the study terminated contract
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06912529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06912529, "Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06912529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*